Jun 8, 2022 · Whether the potential synergy between dose-dense paclitaxel and bevacizumab seen in the setting of platinum-resistant recurrent ovarian cancer will improve outcomes in first-line treatment is being investigated in the ICON8B trial.

The ICON8B study found that giving bevacizumab and weekly chemotherapy (Group 3) was more effective at preventing the cancer coming back or getting worse compared to the standard chemotherapy with bevacizumab (Group 1).

Sep 22, 2019 · ICON8B. A phase 3 randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer

ICON8B, a 3-arm trial, compared BEV+q3wCT versus (vs) BEV+q3wCddwT vs q3wCddwT in high-risk stage III (residual disease >1cm diameter after primary surgery or requirement for primary chemotherapy) and stage IV EOC.

ICON8B: A trial of chemotherapy and bevacizumab in ovarian cancer. Trial at a glance. Closed trial. Cancer type: Epithelial – high-grade serous and endometrioid; Treatment stage: Primary treatment; Acronym: ICON8B

ICON8B is a randomised two-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

icon8/icon8b An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

ICON8B: A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to standard three weekly chemotherapy and bevacizumab for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer Acronym ICON8 and ICON8B

Download design elements for free: icons, photos, vector illustrations, and music for your videos. All the assets made by designers → consistent quality ⚡️.

A phase III randomised trial investigating the combination of dose-fractionated chemotherapy & bevacizumab compared to either strategy alone for the first line treatment of women with newly diagnosed high risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.